Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Valerie Northcutt"'
2
In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor
Autor: John Babiak, Nicole Risher, Marla Weetall, Diksha Kaushik, Shirley Yeh, Kylie O'Keefe, Valerie Northcutt, Ronald Kong, Young-Choon Moon, Ellen Welch, Lachlan Molony, Jiyuan Ma
Publikováno v: Xenobiotica. 52:152-164
Emvododstat was identified as a potent inhibitor of dihydroorotate dehydrogenase and is now in clinical development for the treatment of acute myeloid leukaemia and COVID-19. The objective of this paper is to evaluate the metabolism, pharmacokinetics
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a7c5db3c661d10933b66bd6c7f98a4e
https://doi.org/10.1080/00498254.2021.2010287
Zobrazit plný text záznamu
3
Ataluren metabolism: Ataluren-O-1β-acyl glucuronide is a stable circulating metabolite in mouse, rat, dog and human
Autor: Neil Gregory Almstead, Joseph M. Colacino, Nicole Risher, Valerie Northcutt, Ronald Kong, Ellen Welch, Jiyuan Ma, Young-Choon Moon, Marla Weetall
Publikováno v: Drug Metabolism and Pharmacokinetics. 38:100393
Ataluren is an aromatic acid derivative with a 1,2,4-oxodiazole moiety. Ataluren-O-1β-acyl glucuronide is a prominent circulatory metabolite in mice, rats, dogs, and humans following oral administration of ataluren. The objective of this paper was t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05204623d2470727182d6349aa73f196
https://doi.org/10.1016/j.dmpk.2021.100393
Zobrazit plný text záznamu
4
Metabolism and Disposition of Ataluren after Oral Administration to Mice, Rats, Dogs, and Humans
Autor: Elizabeth Goodwin, Valerie Northcutt, Neil Gregory Almstead, Joseph McIntosh, Ronald Kong, Seongwoo Hwang, John Babiak, Jiyuan Ma
Publikováno v: Drug metabolism and disposition: the biological fate of chemicals. 48(4)
Ataluren is a unique small molecule developed for the treatment of diseases caused by nonsense mutations, which result in premature termination of ribosomal translation and lack of full-length protein production. This study investigated the in vivo m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34cb380bc24dad9696f3e5743cd1a33b
https://pubmed.ncbi.nlm.nih.gov/31980502
Zobrazit plný text záznamu
5
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress‐Regulated Protein Translation
Autor: Young-Choon Moon, Marla Weetall, R. Spiegel, Stuart W. Peltz, Samit Hirawat, Neil Gregory Almstead, John Babiak, Liangxian Cao, Valerie Northcutt, Peter Riebling, Joseph M. Colacino, Mandar V. Dali, Thomas W. Davis, Gary Elfring
Publikováno v: Clinical Pharmacology in Drug Development
PTC299 is a novel small molecule that specifically blocks the production of protein from selected mRNAs that under certain conditions use noncanonical ribosomal translational pathways. Hypoxia, oncogenic transformation, and viral infections limit nor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0c9b02748d1f5ce68203dfe0359fb55
http://europepmc.org/articles/PMC5066743
Zobrazit plný text záznamu
6
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
Autor: H. Blau, Langdon L. Miller, Malka Nissim-Rafinia, Valerie Northcutt, Batsheva Kerem, Samit Hirawat, Joseph Rivlin, Gary Elfring, Eitan Kerem, S. Armoni, Michael Cohen, Micha Aviram, David Shoseyov, Michael Wilschanski, Yasmin Yaakov
Publikováno v: The Lancet. 372:719-727
In about 10% of patients worldwide and more than 50% of patients in Israel, cystic fibrosis results from nonsense mutations (premature stop codons) in the messenger RNA (mRNA) for the cystic fibrosis transmembrane conductance regulator (CFTR). PTC124
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2759dc2ebcf66408d1d07c6a895800dc
https://doi.org/10.1016/s0140-6736(08)61168-x
Zobrazit plný text záznamu
8
Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single- and Multiple-Dose Administration to Healthy Male and Female Adult Volunteers
Autor: Valerie Northcutt, Gary Elfring, William D. Ju, Eileen M. Leonard, Sergey Paushkin, Langdon L. Miller, Seongwoo Hwang, Samit Hirawat, Neil Gregory Almstead, Stuart W. Peltz, Ellen Welch
Publikováno v: The Journal of Clinical Pharmacology. 47:430-444
Nonsense (premature stop codon) mutations are causative in 5% to 15% of patients with monogenetic inherited disorders. PTC124, a 284-Dalton 1,2,4-oxadiazole, promotes ribosomal readthrough of premature stop codons in mRNA and offers therapeutic poten
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e75342edba18ba33312cf60928b47ac
https://doi.org/10.1177/0091270006297140
Zobrazit plný text záznamu
9
Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
Autor: A. Reha, Jay A. Barth, Carsten G. Bönnemann, Brenda Wong, Stuart W. Peltz, Valerie Northcutt, Jacinda B. Sampson, Kevin M. Flanigan, H. Lee Sweeney, Richard S. Finkel, Gary Elfring
Publikováno v: PLoS ONE
PLoS ONE, Vol 8, Iss 12, p e81302 (2013)
Background Approximately 13% of boys with Duchenne muscular dystrophy (DMD) have a nonsense mutation in the dystrophin gene, resulting in a premature stop codon in the corresponding mRNA and failure to generate a functional protein. Ataluren (PTC124)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67c9de85a14d359da7c456aedde049ee
http://europepmc.org/articles/PMC3859499
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje